Study of Pimicotinib for Japanese Patients with TGCT
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new drug called pimicotinib for people in Japan with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. It aims to see if the drug can help with pain and stiffness caused by the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with TGCT that cannot be surgically removed.
- Your worst pain or stiffness from TGCT in the last 2 weeks has been at least 4 out of 10.
- You are generally active and able to do light work or daily activities (ECOG score 0 or 1).
- Your liver, kidneys, and blood counts are within acceptable ranges.
- You have not had certain heart conditions, recent stroke, or serious stomach bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug (DCC-3014) for people with TGCT, a non-cancerous joint tumor. The drug may help reduce pain and improve joint movement without the risks of surgery.
This study is collecting real-world data from people with TGCT who have been prescribed vimseltinib. It is not testing the drug itself — it simply tracks your experience to help doctors understand how the treatment works outside of a clinical trial.
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
This trial tests whether taking a new drug (pimicotinib) before surgery can shrink the tumor and make surgery more effective, compared to having surgery right away. It is for people with a type of benign but aggressive joint tumor called diffuse TGCT.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
This trial tests a targeted drug called pemigatinib for advanced solid tumors that have a specific change in the FGFR gene. The goal is to see if the drug can slow tumor growth for people who have few other treatment options.
Hear when a new Tenosynovial Giant Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.